CD45RB-targeting strategies for promoting long-term allograft survival and preventing chronic allograft vasculopathy

Transplantation

Volumn 75, Issue 8, 2003, Pages 1142-1146

  Sho, Masayuki ^a,b,d   Harada, Hiroshi ^a   Rothstein, David M ^c   Sayegh, Mohamed H ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CD45RB ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45RB; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CHRONIC GRAFT REJECTION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; GRAFT SURVIVAL; HEART GRAFT; HISTOPATHOLOGY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; TREATMENT OUTCOME; VASCULAR DISEASE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD45; ANTIGENS, CD80; BLOOD GROUP INCOMPATIBILITY; CD40 LIGAND; CHRONIC DISEASE; CORONARY DISEASE; CYCLOSPORINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SIROLIMUS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037469016     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000060567.48258.9D     Document Type: Conference Paper

References (29)

1. Chan AC, Desai DM, Weiss A. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu Rev Immunol 1994; 12: 555.
2. Trowbridge IS, Thomas ML. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 1994; 12: 85.
3. Fecteau S, Basadonna GP, Freitas A, et al. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat Immunol 2001; 2(1): 58.
4. Zhong RZ, Lazarovits AI. Monoclonal antibody against CD45RB for the therapy of rejection and autoimmune diseases. J Mol Med 1998; 76(8): 572.
5. + T cells. J Immunol 1990; 144(9): 3288.
6. Onodera H, Motto DG, Koretzky GA, et al. Differential regulation of activation-induced tyrosine phosphorylation and recruitment of SLP-76 to Vav by distinct isoforms of the CD45 protein-tyrosine phosphatase. J Biol Chem 1996; 271(36): 22225.
7. Ko S, Jager MD, Tsui TY, et al. Long-term allograft acceptance induced by single dose anti-leukocyte common antigen (RT7) antibody in the rat. Transplantation 2001; 71(8): 1124.
8. Zhang Z, Lazarovits A, Grant D, et al. CD45RB monoclonal antibody induces tolerance in the mouse kidney graft, but fails to prevent small bowel graft rejection. Transplant Proc 1996; 28(5): 2514.
9. Parry N, Lazarovits AI, Wang J, et al. Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB. J Heart Lung Transplant 1999; 18(5): 441.
10. Wang P, Zhu L, Liu T, et al. Intragraft CD45 RO gene expression is an early marker to detect small bowel allograft rejection in rats. Microsurgery 1999; 19(7): 348.
11. Rothstein DM, Livak MF, Kishimoto K, et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001; 166(1): 322.
12. Sho M, Sandner SE, Najafian N, et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg 2002; 236(5): 667.
13. Smiley ST, Csizmadia V, Gao W, et al. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation 2000; 70(3): 415.
14. Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5(11): 1298.
15. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice: the role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16(4): 343.
16. Chen ZH. A technique of cervical heterotopic heart transplantation in mice. Transplantation 1991; 52(6): 1099.
17. Russell ME, Hancock WW, Akalin E, et al. Chronic cardiac rejection in the LEW to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996; 97(3): 833.
18. Basadonna GP, Auersvald L, Khuong CQ, et al. Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc Natl Acad Sci USA 1998; 95(7): 3821.
19. Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19: 565.
20. Oosterwegel MA, Greenwald RJ, Mandelbrot DA, et al. CTLA-4 and T cell activation. Curr Opin Immunol 1999; 11(3): 294.
21. Sho M, Yamada A, Najafian N, et al. Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25(+) cells, and the alloreactive t cell clone size. J Immunol 2002; 169(7): 3744.
22. Alegre ML, Noel PJ, Eisfelder BJ, et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 1996; 157(11): 4762.
23. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483.
24. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999; 162(5): 2775.
25. Vanasek TL, Khoruts A, Zell T, et al. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J Immunol 2001; 167(10): 5636.
26. Ozkaynak E, Gao W, Shemmeri N, et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2(7): 591.
27. Dai Z, Konieczny BT, Baddoura FK, et al. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol 1998; 161(4): 1659.
28. Tran HM, Nickerson PW, Restifo AC, et al. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment. J Immunol 1997; 159: 2232.
29. Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Thl cytokines but spares Th2. J Exp Med 1995; 181(5): 1869.